Adicet Bio, Inc. (ACET)
$5.35
-0.32 (-5.64%)
Rating:
Recommendation:
-
| Symbol | ACET |
|---|---|
| Price | $5.35 |
| Beta | 1.913 |
| Volume Avg. | 0.46M |
| Market Cap | 229.823M |
| Shares () | - |
| 52 Week Range | 4.61-21.87 |
| 1y Target Est | - |
| DCF Unlevered | ACET DCF -> | |
|---|---|---|
| DCF Levered | ACET LDCF -> | |
| ROE | -28.89% | Sell |
| ROA | -26.52% | Sell |
| Operating Margin | - | |
| Debt / Equity | 13.12% | Neutral |
| P/E | -1.95 | Sell |
| P/B | 0.75 | Buy |
Latest ACET news
About
Download (Excel)Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA
Healthcare
Biotechnology
NASDAQ Global Market
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.